Belgium-based clinical stagebiopharmaceutical company arGEN-X has progressed its fourth therapeutic candidate, ARGX-112, into formal preclinical development. The new human antibody ARGX-112 neutralizes both IL20 and IL22 signaling through ...
Tags: preclinical development, clinical stagebiopharmaceutical, Medicine